Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...

Articles Figures Tables About

Challenges and Refinements

Before the disaster in Europe and Canada, thalidomide had been submitted to the FDA for approval in the United States. The FDA did not consider the safety tests of Chemie Griinenthal to be adequate and withheld approval of thalidomide. The United States was therefore spared the thalidomide disaster. Withholding approval for thalidomide is considered to be one of the triumphs of the FDA in protecting public safety.1 [Pg.10]

The case of fen-phen highlights the complexity of evaluating the safety of a drug. Upon approval, all the potential problems of a drug are difficult to anticipate. This is especially true if physiological problems do not manifest themselves during the animal and [Pg.10]

Sneader, W. Drug Prototypes and their Exploitation. Chichester, UK Wiley Sons, 1996. [Pg.12]

Curcumin Derived from Turmeric (Curcuma longa)  [Pg.12]

A Spice for All Seasons. In D. Bagchi (ed.) Phytopharmaceuticals in Cancer Chemoprevention (Chapter 23). Boca Raton, FL Chemical Rubber Company, 2005. [Pg.12]


Figure 13.10 Depiction of the recursive process used by NCTR to develop QSAR models for predicting ER binding. The process starts with an initial set of chemicals from the literature for QSAR modeling. Next, the preliminary QSAR models are used prospectively to define a set of chemicals that will further improve the model s robustness and predictive capability. The new chemicals are assayed, and these data are then used to challenge and refine the QSAR models. Validation of the model is critical. The process emphasizes the living model concept. Figure 13.10 Depiction of the recursive process used by NCTR to develop QSAR models for predicting ER binding. The process starts with an initial set of chemicals from the literature for QSAR modeling. Next, the preliminary QSAR models are used prospectively to define a set of chemicals that will further improve the model s robustness and predictive capability. The new chemicals are assayed, and these data are then used to challenge and refine the QSAR models. Validation of the model is critical. The process emphasizes the living model concept.
Like the aimealing of steel, the processes were challenged and refined by many forces. This included the evolution of global markets and increasing business complexity. Many companies failed first before they could go forward. The greatest moves forward came not from success, but from failure. Material event after material event created a boardroom understanding of why bricks matter. This book is a synopsis of this journey. [Pg.321]

Heinrich, G., M. Valais, M. Passot and B. Chapotel (1991), Mutations of world refining challenge and answers . I3th World Petroleum Congress, Buenos Aires, Vol. 3, p. 189-198. [Pg.456]

It would be impossible to memorize the names of every molecule, because there are too many to even count. Instead, we have a very systematic way of naming molecules. What you need to learn are the rules for naming molecules (these rules are referred to as lUPAC nomenclature). This is a much more manageable task than memorizing names, but even these rules can become challenging to master. There are so many of them, that you could study only these rules for an entire semester and still not finish all of them. The larger the molecules get, the more rules you need to account for every kind of possibility. In fact, the list of rules is regularly updated and refined. [Pg.83]

The challenges in this process are significant. Gasoline-fueled (and diesel-fueled) vehicles powered by internal combustion engines (ICEs) won the market competition over other motive systems and their performance has since been improved and refined for more than 100 years. Furthermore, a vast infrastructure has been established that manufactures, maintains, and fuels the current vehicular fleet in the United States. [Pg.327]

As indicated, a progressively larger portion of activities in a clinical trial matrix is controlled by function-specific software, provided by IT vendors, CROs, or sponsors. This may be problemahc in study sites that execute multiple studies for different sponsors simultaneously, all having different SOPs, data collection procedures and payment policies. Standardized site-specific software is being developed and refined to accommodate this problem, but currently busy study sites can find this accommodation challenging. [Pg.417]

CNS Tumors in Children. Pediatric tumors located in the CNS are particularly challenging and deserve highly refined techniques of radiation therapy like proton therapy (Fig. 18) [40-42]. The preliminary results from Loma Linda, MGH/HCL, and Centre de Proton Therapie d Orsay are promising and show an excellent immediate and late tolerance. [Pg.766]


See other pages where Challenges and Refinements is mentioned: [Pg.322]    [Pg.1]    [Pg.9]    [Pg.310]    [Pg.460]    [Pg.495]    [Pg.5]    [Pg.238]    [Pg.322]    [Pg.1]    [Pg.9]    [Pg.310]    [Pg.460]    [Pg.495]    [Pg.5]    [Pg.238]    [Pg.253]    [Pg.131]    [Pg.166]    [Pg.96]    [Pg.515]    [Pg.173]    [Pg.26]    [Pg.531]    [Pg.132]    [Pg.290]    [Pg.13]    [Pg.475]    [Pg.247]    [Pg.50]    [Pg.405]    [Pg.163]    [Pg.166]    [Pg.288]    [Pg.269]    [Pg.444]    [Pg.536]    [Pg.99]    [Pg.96]    [Pg.131]    [Pg.166]    [Pg.515]    [Pg.63]    [Pg.269]    [Pg.520]    [Pg.509]    [Pg.46]    [Pg.420]    [Pg.140]   


SEARCH



© 2024 chempedia.info